⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1211358 | 0.83 | LOXL2 (0.59) | — | |
| SCHEMBL1211287 | 0.79 | LOXL2 (0.55) | — | |
| SCHEMBL16675785 | 0.79 | PRKCI (0.64) | — | |
| SCHEMBL2642497 | 0.77 | — | — | |
| SCHEMBL1348600 | 0.77 | — | — | |
| SCHEMBL29893902 | 0.77 | — | — | |
| SCHEMBL6468413 | 0.77 | — | — | |
| SCHEMBL3994643 | 0.77 | — | — | |
| SCHEMBL7413054 | 0.77 | — | — | |
| SCHEMBL501592 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119056265-A | Reverse osmosis membrane, high-recovery reverse osmosis device containing reverse osmosis membrane and application of reverse osmosis membrane | 杭州上拓环境科技股份有限公司 | 2024-12-03 | — | — | CN | claimed |
| CN-117089054-A | Method for preparing polyurethane modified alkyd resin and preparation of high-gloss wear-resistant varnish | 扬州市祥华新材料科技有限公司 | 2023-11-21 | — | — | CN | claimed |
| CN-116478413-A | Method for modifying alkyd resin by acrylic acid prepolymer block type and application thereof | 扬州市祥华新材料科技有限公司 | 2023-07-25 | — | — | CN | claimed |
| CN-116444776-A | Method for preparing polyurethane modified alkyd resin and preparation of high-gloss wear-resistant varnish | 扬州市祥华新材料科技有限公司 | 2023-07-18 | — | — | CN | claimed |
| CN-102712589-B | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG | 2015-05-13 | — | — | CN | claimed |
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | BIOGEN MA INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4577536-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | Hotspot Therapeutics, Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| US-20250171434-A1 | SEC61 INHIBITORS AND USE THEREOF | ENODIA THERAPEUTICS SAS (FR) | 2025-05-29 | — | — | US | disclosed |
| EP-3936192-B1 | PYRROLOPYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2025-04-09 | — | — | EP | disclosed |
| CN-117229205-B | Preparation method and pharmaceutical application of phenyl acrylamide RHbDD1 inhibitor | 中国医学科学院基础医学研究所 | 2025-03-21 | — | — | CN | disclosed |
| US-12240855-B2 | Pyrrolopyrazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-03-04 | — | — | US | disclosed |
| EP-4486451-A1 | SEC61 INHIBITORS AND USE THEREOF | Kezar Life Sciences, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| EP-1194425-B1 | SUBSTITUTED BENZIMIDAZOLE | AVENTIS PHARMA GMBH (DE) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004083235-A2 | TIE-2 MODULATORS AND METHODS OF USE | EXELIXIS INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| EP-1194425-A1 | SUBSTITUTED BENZIMIDAZOLE | Aventis Pharma Deutschland GmbH (DE) | 2002-04-10 | — | — | EP | disclosed |
| US-6358978-B1 | FOR THERAPY AND PROPHYLAXIS OF RHEUMATOID ARTHRITIS (IN THE CASE OF INFLAMMATION), OSTEOARTHRITIS, ASTHMA, CARDIAC INFARCT, ALZHEIMER'S DISEASE, OR ATHEROSCLEROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-03-19 | — | — | US | disclosed |
| US-6214847-B1 | TREATMENT OF COGNITIVE OR NEUROLOGICAL DYSFUNCTION | DUPONT PHARMACEUTICALS COMPANY | 2001-04-10 | — | — | US | disclosed |
| WO-2001000610-A1 | SUBSTITUTED BENZIMIDAZOLE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-01-04 | — | — | WO | disclosed |
| EP-1003722-A1 | CRYSTALLINE 10,10-BIS((2-FLUORO-4-PYRIDINYL)METHYL)-9(10H)-ANTHRACENONE AND AN IMPROVED PROCESS FOR PREPARING THE SAME | Du Pont Pharmaceuticals Company (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999009010-A1 | CRYSTALLINE 10,10-BIS((2-FLUORO-4-PYRIDINYL)METHYL)-9(10H)-ANTHRACENONE AND AN IMPROVED PROCESS FOR PREPARING THE SAME | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |